Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer

References

• Vredenburgh JJ, Silva 0, Broadwater G et al. The signifi- cance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997;3:91–7.
   Google Scholar
• Passos-Coelho JL, Ross AA, Moss TJ et al. Absence of breastcancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granu-locyte-macrophage colony stimulating factor. Blood 1995; 85:1138–43.
   PubMed Web of Science ®Google Scholar
• Passos-Coelho J, Ross AA, Kahn DJ et al Similar breast can-cer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophos-phamide followed by growth factor. 7 Clin Oncol 1996;14: 2569–75.
   PubMed Web of Science ®Google Scholar
• Pecora AL, Lazarus H, Cooper B et al Breast cancer contam-ination in peripheral blood stem cell collections associates with bone marrow disease and type of mobilization. Blood 1997;90\(Suppl 1):abstract 434.
   Google Scholar
• Kahn DG, Prilutskaya M, Cooper B et al. The relationshipbetween the incidence of tumor cell contamination and number of phereses for stage IV breast cancer. Blood 1997; 90\(Suppl 1):abstract 2514.
   Google Scholar
• Rill DR, Santana VM, Roberts WM et al Direct demonstra-tion that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380–5.
   PubMed Web of Science ®Google Scholar
• Brenner MK, Rill DR, Moen RC. Gene marking to trace origin of relapse after autologous bone marrow transplant-ation. Lancet 1993;341:85–6.
   Google Scholar
• Deisseroth AB, Zu Z, Claxton D. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068–74.
   Google Scholar
• Grande M, Barbu V, Van Den Akker J et al Autologous bonemarrow transplantation in ALL: relapse linked to infusion of tumor cells with the back-up marrow. Bone Marrow Transplant 1994;14:477–80.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Kessinger A, Mann S et al Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the harvested marrow or infused hematopoietic harvest. 7 Clin Oncol 1996; 14:214–19.
   PubMed Web of Science ®Google Scholar
• Fields KK, Elfenbein GJ, Trudeau WL et al Clinical signifi-cance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. 7 Clin Oncol 1996;14: 1868–76.
   Google Scholar
• Brockstein BE, Ross AA, Moss TJ et al. Tumor cell contam-ination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. Hematotherapy 1996;5:617–24.
   PubMedGoogle Scholar
• Gluck S, Ross AA, Goldstein L et al Detection of breast can-cer cells in the apheresis product and their potential clinical significance. Blood 1996;88(Suppl 1):605a.
   Google Scholar
• Gribben J, Freedman A, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl 7 Med 1991;325:1525–31.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bc1-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449–57.
   PubMed Web of Science ®Google Scholar
• Moss TJ, Umiel T, Herzig RM et al. The presence of clono-genic breast cancer cells in peripheral blood stem cell products correlates with an extremely poor prognosis for patients with stage IV disease. Blood 1997;90\(Suppl 1): abstract 4570.
   Google Scholar
• Kemshead JT. The immunomagnetic manipulation of bone marrow. In: Gee AP, editor. Bone marrow processing and purg-ing A practical guide. CRC Press. 1991:293–305.
   Google Scholar
• Kvalheim G, Wang MY, Pharo A et al Purging of tumor cells from leucopheresis products: experimental and clinical aspects. 7 Hematother 1996;5:427–36.
   PubMedGoogle Scholar
• Fruehauf S, Haas R, Zeller WJ, Hunstein W. CD34 selection for purging in multiple myeloma and analysis of CD34 + B cell precursors. Stem Cells Dayt 1994;12:95–102.
   PubMed Web of Science ®Google Scholar
• Mapara MY, Körner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical staining and reverse-transcriptase chain reaction. Blood 1997;89:337–43.
   PubMed Web of Science ®Google Scholar
• Preti RA, Nadasi S, Murawski et al. Single step positive/negative purging for breast cancer using the Isolex 300i magnetic cell separator. Blood 1997;90(Suppl 1): 4306.
   Google Scholar
• Loudavaris M, Unverzagt K, Martinson J et al Simultaneous positive/negative selection for T cell depletion with the Isolex 300i magnetic cell separator. Blood 1997;90(Suppl 1):1874.
   Google Scholar
• Hardwick RA, Kulchinski D, Mansour V. Design of large-scale separation systems for positive and negative immunomagnetic selection of cells using superparamag-netic microspheres. 7 Hematotherapy 1992;1: 386–90.
   Google Scholar
• Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. 7 Hematotherapy 1992;1:131–42.
   Google Scholar
• Civin CI, Strauss LC, Brovall C. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. y Immunol 1984;133:157.
   Google Scholar
• Ugelstad J, Berge A, Schmidt R. New developments in production and application of monosized polymer particles. In: Reichert and Geisler, editors. Polymer reaction kinetics. Huthig & Wepf, Basel, 1986:77–86.
   Google Scholar
• Chang M, Richards G, Rembaum A. Polyacrolein micros-pheres: preparation and characteristics. Methods Enzymol 1985;112: 150.
   Google Scholar
• Hansen M, Mansour V, Yacob D et al. Performance of a novel peptide CD34+ releasing agent for the Isolex system. Bone Marrow Transplant 1996;17(Suppl 1):S29.
   Google Scholar
• Rubbi CP, Patel D, Rickwood D. Evidence of surface antigen detachment during incubation of cells with immuno- mag-netic beads. 7 Immunol Methods 1993;166: 233–41.
   Google Scholar
• Silvestri F, Banavali S, Savignano C et al. CD34 cell selec-tion: focus on immunomagnetic beads and chymopapain. Int .7 Artif Organs 1993;16\(Suppl 5):96–101.
   Google Scholar
• Stiff PJ, Koester AR, Weidner MK. Autologous bone marrow transplantation using unfractionated cells cryopre-served in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987;70:974–80.
   Google Scholar
• Lazarus HM, Andersen J, Chen MG et al. Recombinant GM-CSF after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 1991;78: 830–7.
   Google Scholar
• Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytome-try. y Hematotherapy 1996;5:213–8.
   PubMedGoogle Scholar
• Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose ther-apy. 7 Clin Onco/ 1992;10:102–10.
   PubMed Web of Science ®Google Scholar
• Fields KK Agaliotis DP, Janssen WE et al. High dose chemotherapy and the treatment of metastatic breast can-cer: Selecting the regimen and the source of stem cells. Cancer Control 1994;1:213–18.
   Google Scholar
• Pecora AL, Lazarus HL, Stadtmauer EA et al. Effect of induction chemotherapy and tandem cycles of high dose chemotherapy on outcomes in autologous stem cell trans-plant for metastatic breast cancer. Bone Marrow Transplant 2000; In press.
   Google Scholar
• Stadtmauer EA, O'Neill A, Goldstein LJ et al Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl .7 Med 2000;342:1069–76.
   PubMed Web of Science ®Google Scholar
• Passos-Coehho J, Ross A, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperox-ycyclophosphamide. Cancer Res 1994;54:2366–71.
   Google Scholar
• Yin AH, Miraglia S, Zanjani ED et al AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002–12.
   PubMed Web of Science ®Google Scholar
• Schiller G, Vescio R, Freyetes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1990,86:390–7.
   Google Scholar
• Friedman J, Lazarus HM, Koc ON. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) trans-plantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000;26: 831–6.
   Google Scholar
• Koc ON, Gerson SL, Phillips GL et al. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment Bone Marrow Transplant 1998;20: 337–43.
   Google Scholar
• Pecora AL, Gleim GW, Preti RA et al. CD34±CD33— cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. 7 Clin Oncol 1998;16: 2093–104.
   Google Scholar